MET and Small-Cell Lung Cancer

Cancers

Francesco Gelsomino¹  Giulio Rossi² 

[1] Medical Oncology Unit 1, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milano, Italy;Operative Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Via del Pozzo 71, 41124 Modena, Italy; E-Mail:

关键词: c-MET;    small-cell lung cancer;    mutations;    c-MET signaling pathway;   

DOI  :  10.3390/cancers6042100

来源: mdpi

【 摘 要 】

Small-cell lung cancer (SCLC) is one of the most aggressive lung tumors. The majority of patients with SCLC are diagnosed at an advanced stage. This tumor type is highly sensitive to chemo-radiation treatment, with very high response rates, but invariably relapses. At this time, treatment options are still limited and the prognosis of these patients is poor. A better knowledge of the molecular biology of SCLC allowed us to identify potential druggable targets. Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression. In this review, we describe briefly all recent literature on the different molecular profiling in SCLC; in particular, we discuss the specific alterations involving c-MET gene and their implications as a potential target in SCLC.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.